Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis
This trial combines the radiotherapy standard of care for multiple brain metastasis patients, whole brain radiation therapy, with 3 intravenous injections of AGuIX® at 100 mg/kg.
- This trial combines the radiotherapy standard of care for multiple brain metastasis patients, whole brain radiation therapy, with 3 intravenous injections of AGuIX® at 100 mg/kg.
- Dr. Olivier de Beaumont, Chief Medical Officer of NH TherAguix says: “The completion of recruitment in NANORAD 2 trial is a critical achievement for NH TherAguix.
- We aim to introduce innovative treatment alternatives for patients coping with multiple brain metastases, addressing unmet medical needs.
- Finally, a clinical benefit according to RECIST v1.1 (partial response or stable disease) was established for 13 over 14 evaluable patients.